Preclinical & Clinical
“The greatest enemy of knowledge is not ignorance; it is the illusion of knowledge.” Stephen Hawking
Italfarmaco is an important player in the Italian pharma industry landscape due to both its products and its R&D activities.
The first area of focus in its Research Centre was a non-steroidal anti-inflammatory drug, marketed in 1984. Subsequently, a protein iron complex was developed for the treatment of anaemia resulting in iron deficiency, today marketed in over 40 countries worldwide. In 1988, the company began the international development of a molecule for treating cerebral cognitive disorders, including both vascular and non-vascular Alzheimer’s disease. In the cardiovascular area it was a pioneer in the development of anti-thrombotic drugs in the chronic treatment of ischemic heart disease and in the prophylaxis and therapy of venous and arterial thrombosis.
Research and Innovation in Therapies for Rare and Complex Diseases
Our present research is centred around neuromuscular disorders, fibrosis and cancer (including oncology supportive care) with a special focus on rare disease. Having focused on Duchenne muscular dystrophy (DMD) we are now undertaking a Phase III clinical trial in Polycythemia Vera, a rare haematological cancer. Our R&D group works with small molecules, peptides, and monoclonal antibodies to best suit each target’s biology.
Enhancing Therapeutic Options: New Formulations and Complex Biosimilars
In addition to the development of new chemical entities, Italfarmaco’s R&D group also develops new formulations of established drugs to better respond to patient needs and generics/biosimilars of complex molecules. Examples developed to market in Europe, USA and Rest of the World are the liquid formulations of antidepressants or hypnotic agents and a treatment for Amiotrophic Lateral Sclerosis (ALS). Regarding the development of generics/biosimilar of complex molecules, Italfarmaco’s R&D group has developed generics/biosimilars of enoxaparin and glatiramer.
Our Focus
The goal of Italfarmaco’s research activity is to provide caregivers and patients with new treatment options, to improve health and to ensure a better quality of life for patients.
Our Focus
The goal of Italfarmaco’s research activity is to provide caregivers and patients with effective and safe drugs, to improve the health and to ensure a better quality of life of patients.